Combination therapy with liposomal neuroprotectants and tissue plasminogen activator for treatment of ischemic stroke

FASEB Journal

Volumn 31, Issue 5, 2017, Pages 1879-1890

  Fukuta, Tatsuya ^a,b   Asai, Tomohiro ^a   Yanagida, Yosuke ^a   Namba, Mio ^a   Koide, Hiroyuki ^a   Shimizu, Kosuke ^a   Oku, Naoto ^a  

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b JAPAN SOCIETY FOR THE PROMOTION OF SCIENCE   (Japan)

Author keywords

Blood brain barrier; Drug delivery system; Fasudil; Liposome; Photochemically induced thrombosis

Indexed keywords

ALTEPLASE; FASUDIL; GELATINASE A; GELATINASE B; LIPOSOME; NEUROPROTECTIVE AGENT; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; BRAIN DAMAGE; BRAIN HEMORRHAGE; CHRONOPHARMACOLOGY; COMBINATION DRUG THERAPY; CONTINUOUS INFUSION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME ACTIVITY; EXPERIMENTAL CEREBRAL ISCHEMIA; FIBRINOLYTIC THERAPY; INFUSION PUMP; LIPOSOMAL DELIVERY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOTOR DYSFUNCTION; NEUROPROTECTION; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PHOTOCHEMICALLY INDUCED THROMBOSIS; PRIORITY JOURNAL; RAT; RISK REDUCTION; THERAPEUTIC INDEX; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ANIMAL; BRAIN ISCHEMIA; DISEASE MODEL; DRUG EFFECTS; METABOLISM; MULTIMODALITY CANCER THERAPY; PROCEDURES; REPERFUSION INJURY; STROKE; WISTAR RAT;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN ISCHEMIA; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; LIPOSOMES; MALE; NEUROPROTECTIVE AGENTS; RATS, WISTAR; REPERFUSION INJURY; STROKE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 85019466755     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.201601209R     Document Type: Article

References (44)

1. Iadecola, C., and Anrather, J. (2011) Stroke research at a crossroad: asking the brain for directions. Nat. Neurosci. 14, 1363-1368
2. Lo, E. H. (2008) A new penumbra: transitioning from injury into repair after stroke. Nat. Med. 14, 497-500
3. Vivien, D., Gauberti, M., Montagne, A., Defer, G., and Touzé, E. (2011) Impact of tissue plasminogen activator on the neurovascular unit: from clinical data to experimental evidence. J. Cereb. Blood Flow Metab. 31, 2119-2134
4. Jickling, G.C., Liu, D., Stamova, B., Ander,B. P., Zhan, X., Lu, A., and Sharp, F. R. (2014) Hemorrhagic transformation after ischemic stroke in animals and humans. J. Cereb. Blood FlowMetab. 34, 185-199
5. Shichita, T., Hasegawa, E., Kimura, A., Morita, R., Sakaguchi, R., Takada, I., Sekiya, T., Ooboshi, H., Kitazono, T., Yanagawa, T., Ishii, T., Takahashi, H., Mori, S., Nishibori, M., Kuroda, K., Akira, S., Miyake, K., and Yoshimura, A. (2012) Peroxiredoxin family proteins are key initiatorsof post-ischemic inflammationinthe brain. Nat.Med. 18, 911-917
6. Ginsberg, M. D. (2008) Neuroprotection for ischemic stroke: past, present and future. Neuropharmacology 55, 363-389
7. Chamorro, Á., Dirnagl, U., Urra, X., and Planas, A. M. (2016) Neuroprotection in acute stroke: targeting excitotoxicity, oxidative and nitrosative stress, and inflammation. Lancet Neurol. 15, 869-881
8. Fagan, S.C.,Hess,D. C.,Hohnadel, E. J., Pollock, D.M., and Ergul, A. (2004) Targets for vascular protection after acute ischemic stroke. Stroke 35, 2220-2225
9. Del Zoppo, G. J. (2009) Relationship of neurovascular elements to neuron injury during ischemia. Cerebrovasc. Dis. 27(Suppl 1), 65-76
10. Ishii, T., Asai, T., Oyama, D., Fukuta, T., Yasuda, N., Shimizu, K., Minamino,T., andOku,N. (2012)Ameliorationof cerebral ischemiareperfusion injury based on liposomal drug delivery system with asialo-erythropoietin. J. Control. Release 160, 81-87
11. Fukuta, T., Ishii, T., Asai, T., Sato, A., Kikuchi, T., Shimizu, K., Minamino, T., and Oku, N. (2015) Treatment of stroke with liposomal neuroprotective agents under cerebral ischemia conditions. Eur. J. Pharm. Biopharm. 97(Pt A), 1-7
12. Ishii,T.,Asai,T.,Oyama,D.,Agato, Y., Yasuda,N., Fukuta,T., Shimizu, K., Minamino, T., and Oku, N. (2013) Treatment of cerebral ischemia-reperfusion injury with PEGylated liposomes encapsulating FK506. FASEB J. 27, 1362-1370
13. O'Collins, V. E., Macleod, M. R., Donnan, G. A., and Howells, D. W. (2012) Evaluation of combination therapy in animal models of cerebral ischemia. J. Cereb. Blood Flow Metab. 32, 585-597
14. Sutherland, B. A.,Minnerup, J., Balami, J. S., Arba, F., Buchan, A.M., and Kleinschnitz, C. (2012) Neuroprotection for ischaemic stroke: translation from the bench to the bedside. Int. J. Stroke 7, 407-418
15. Fisher, M., Dávalos, A., Rogalewski, A., Schneider, A., Ringelstein, E. B., and Schäbitz, W.-R. (2006) Toward a multimodal neuroprotective treatment of stroke. Stroke 37, 1129-1136
16. Wang, X., Tsuji, K., Lee, S. R., Ning, M., Furie, K. L., Buchan, A. M., and Lo, E. H. (2004) Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke. Stroke 35(Suppl 1)2726-2730
17. Wang, W., Li, M., Chen, Q., and Wang, J. (2015) Hemorrhagic transformationafter tissueplasminogenactivator reperfusiontherapy for ischemic stroke: mechanisms, models, and biomarkers. Mol. Neurobiol. 52, 1572-1579
18. Mueller, B. K., Mack, H., and Teusch, N. (2005) Rho kinase, a promising drug target for neurological disorders. Nat. Rev. Drug Discov. 4, 387-398
19. Shibuya, M., Hirai, S., Seto, M., Satoh, S, and Ohtomo, E.; Fasudil Ischemic Stroke Study Group (2005) Effects of fasudil in acute ischemic stroke: results of a prospective placebo-controlled doubleblind trial. J. Neurol. Sci. 238, 31-39
20. Niego, B., Freeman, R., Puschmann, T. B., Turnley, A. M., and Medcalf, R. L. (2012) tPA-specific modulation of a human blood-brain barrier model involves plasmin-mediated activation of the Rho kinase pathway in astrocytes. Blood 119, 4752-4761
21. Ishiguro, M., Kawasaki, K., Suzuki, Y., Ishizuka, F., Mishiro, K., Egashira, Y., Ikegaki, I., Tsuruma, K., Shimazawa, M., Yoshimura, S., Iwama, T., and Hara, H. (2012) A Rho kinase (ROCK) inhibitor, fasudil, prevents matrix metalloproteinase-9-related hemorrhagic transformation in mice treated with tissue plasminogen activator. Neuroscience 220, 302-312
22. Gibson, C. L., Srivastava, K., Sprigg, N., Bath, P.M., and Bayraktutan, U. (2014) Inhibition of Rho-kinase protects cerebral barrier from ischaemia-evoked injury through modulations of endothelial cell oxidative stress and tight junctions. J. Neurochem. 129, 816-826
23. Fukuta, T., Asai, T., Sato, A., Namba, M., Yanagida, Y., Kikuchi, T., Koide, H., Shimizu, K., and Oku, N. (2016) Neuroprotection against cerebral ischemia/reperfusion injury by intravenous administration of liposomal fasudil. Int. J. Pharm. 506, 129-137
24. Umemura, K.,Higo, K., Sakata, T., Yuki, S., Iwata, K., and Yamaguchi, K. (2008) Effects of alteplase, a thrombolytic agent, in a rat photothrombotic middle cerebral artery occlusion model. Pathophysiol. Haemost. Thromb. 36, 245-250
25. Umemura, K., Wada, K., Uematsu, T., and Nakashima, M. (1993) Evaluation of the combination of a tissue-type plasminogen activator, SUN9216, and a thromboxane A2 receptor antagonist, vapiprost, in a rat middle cerebral artery thrombosis model. Stroke 24, 1077-1081, discussion 1081-1082
26. Maeda, M., Furuichi, Y., Ueyama, N., Moriguchi, A., Satoh, N., Matsuoka, N., Goto, T., and Yanagihara, T. (2002) A combined treatment with tacrolimus (FK506) and recombinant tissue plasminogen activator for thrombotic focal cerebral ischemia in rats: increased neuroprotective efficacy and extended therapeutic time window. J. Cereb. Blood Flow Metab. 22, 1205-1211
27. Nagasawa, H., and Kogure, K. (1989) Correlation between cerebral blood flow and histologic changes in a new rat model of middle cerebral artery occlusion. Stroke 20, 1037-1043
28. Tsukada, H., Nishiyama, S., Fukumoto, D.,Kanazawa, M., andHarada, N. (2014) Novel PET probes 18F-BCPP-EF and 18F-BCPP-BF for mitochondrial complex I: a PET study in comparison with 18F-BMS-747158-02 in rat brain. J. Nucl. Med. 55, 473-480
29. Fukuta, T., Ishii, T., Asai, T., Nakamura, G., Takeuchi, Y., Sato, A., Agato, Y., Shimizu, K., Akai, S., Fukumoto, D., Harada, N., Tsukada, H., Kawaguchi, A. T., and Oku, N. (2014) Real-time trafficking of PEGylated liposomes in the rodent focal brain ischemia analyzed by positron emission tomography. Artif. Organs 38, 662-666
30. Yemisci,M.,Gursoy-Ozdemir, Y., Vural,A.,Can,A.,Topalkara,K., and Dalkara,T. (2009) Pericyte contraction induced by oxidative-nitrative stress impairs capillary reflow despite successful opening of an occluded cerebral artery. Nat. Med. 15, 1031-1037
31. Del Zoppo, G. J., and Mabuchi, T. (2003) Cerebral microvessel responses to focal ischemia. J. Cereb. Blood Flow Metab. 23, 879-894
32. Lo, E. H., Wang, X., and Cuzner, M. L. (2002) Extracellular proteolysis in brain injury and inflammation: role for plasminogen activators and matrix metalloproteinases. J. Neurosci. Res. 69, 1-9
33. Su, E. J., Fredriksson, L., Geyer, M., Folestad, E., Cale, J., Andrae, J., Gao, Y., Pietras, K., Mann, K., Yepes, M., Strickland, D. K., Betsholtz, C., Eriksson,U., and Lawrence, D. A. (2008) Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. Nat. Med. 14, 731-737
34. Iadecola,C., andAnrather, J. (2011)The immunology of stroke: from mechanisms to translation. Nat. Med. 17, 796-808
35. Jickling, G.C., Liu,D., Ander, B. P., Stamova, B., Zhan, X., and Sharp, F. R. (2015) Targeting neutrophils in ischemic stroke: translational insights from experimental studies. J. Cereb. Blood Flow Metab. 35, 888-901
36. Cuadrado, E., Ortega, L., Hernández-Guillamon, M., Penalba, A., Fernández-Cadenas, I., Rosell, A., and Montaner, J. (2008) Tissue plasminogen activator (tPA) promotes neutrophil degranulation and MMP-9 release. J. Leukoc. Biol. 84, 207-214
37. Lakhan, S. E., Kirchgessner, A., Tepper, D., and Leonard, A. (2013) Matrix metalloproteinases and blood-brain barrier disruption in acute ischemic stroke. Front. Neurol. 4, 32
38. Justicia,C., Panés, J., Solé, S.,Cervera, A.,Deulofeu, R., Chamorro,A., and Planas, A. M. (2003) Neutrophil infiltration increases matrix metalloproteinase-9 in the ischemic brain after occlusion/ reperfusion of the middle cerebral artery in rats. J. Cereb. Blood Flow Metab. 23, 1430-1440
39. Jin, R., Yang, G., and Li, G. (2010) Inflammatory mechanisms in ischemic stroke: role of inflammatory cells. J. Leukoc. Biol. 87, 779-789
40. Emberson, J., Lees,K.R., Lyden, P.,Blackwell, L.,Albers, G.,Bluhmki, E., Brott, T., Cohen, G., Davis, S., Donnan, G., Grotta, J., Howard, G., Kaste, M., Koga, M., von Kummer, R., Lansberg, M., Lindley, R. I., Murray, G., Olivot, J.M., Parsons, M., Tilley, B., Toni, D., Toyoda, K., Wahlgren, N.,Wardlaw, J.,Whiteley, W., del Zoppo, G. J., Baigent, C., Sandercock, P., and Hacke, W.; Stroke Thrombolysis Trialists' Collaborative Group. (2014) Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet 384, 1929-1935
41. Yagita, Y., Kitagawa, K., Sasaki, T., Terasaki, Y., Todo, K., Omura-Matsuoka, E., Kaibuchi, K., and Hori, M. (2007) Rho-kinase activation in endothelial cells contributes to expansion of infarction after focal cerebral ischemia. J. Neurosci. Res. 85, 2460-2469
42. Satoh, S., Toshima, Y., Hitomi, A., Ikegaki, I., Seto, M., and Asano, T. (2008) Wide therapeutic time window for Rho-kinase inhibition therapy in ischemic brain damage in a rat cerebral thrombosismodel. Brain Res. 1193, 102-108
43. Lo, E. H., Dalkara, T., and Moskowitz, M. A. (2003) Mechanisms, challenges and opportunities in stroke. Nat. Rev. Neurosci. 4, 399-414
44. Murata, Y., Rosell, A., Scannevin, R. H., Rhodes, K. J., Wang, X., and Lo, E. H. (2008) Extension of the thrombolytic time window with minocycline in experimental stroke. Stroke 39, 3372-3377